Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
desloratadine, Quantity: 5 mg
Arrotex Pharmaceuticals Pty Ltd
Tablet, film coated
Excipient Ingredients: lactose monohydrate; pregelatinised starch; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hydrogenated cottonseed oil; dibasic sodium phosphate; maize starch; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin; indigo carmine aluminium lake
Oral
42, 5, 60, 45, 30, 7, 50, 3, 25, 40, 15, 28, 14, 20, 10, 2
(S2) Pharmacy Medicine
The rapid relief of symptoms associated with seasonal allergic rhinitis. The nasal symptoms of allergic rhinits include rhinorrhoea, sneezing and nasal itching. Allergic rhinitis is also associated with non-nasal symptoms such as ocular itching, tearing and itching of the eyes or palate. The relief of symptoms associated with perennial allergic rhinitis. The symptomatic relief of itching and reduction in the size and number of hives associated with chronic idiopathic urticaria.
Visual Identification: Blue, round, biconvex tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2019-12-05